-
公开(公告)号：WO1998022106A1
公开(公告)日：1998-05-28
申请号：PCT/US1997020794
申请日：1997-11-12
Applicant: ABBOTT LABORATORIES
Inventor： ABBOTT LABORATORIES , LIPARI, John , AL-RAZZAK, Laman, A. , GHOSH, Soumojeet , GAO, Rong , KAUL, Dilip
IPC: A61K31/425
CPC classification number: A61K38/55 , A61K9/4858 , A61K31/341 , A61K31/426 , A61K31/4433 , A61K31/47 , A61K31/4704 , A61K31/4725 , A61K31/496 , A61K31/513 , A61K31/5375 , A61K31/551 , A61K38/05 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/44 , Y02A50/465
Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelating capsules or soft elastic capsules (SEC).
Abstract translation: 对于作为HIV蛋白酶抑制剂的化合物，公开了提供改善的口服生物利用度的液体药物组合物。 特别地，组合物包含（a）HIV蛋白酶抑制剂和任选的（b）表面活性剂的药学上可接受的有机溶剂中的溶液。 组合物可任选地包封在硬胶囊或软弹性胶囊（SEC）中。
-
公开(公告)号：WO1995007696A1
公开(公告)日：1995-03-23
申请号：PCT/US1994009788
申请日：1994-08-30
Applicant: ABBOTT LABORATORIES
Inventor： ABBOTT LABORATORIES , AL-RAZZAK, Laman, A. , MARSH, Kennan, C. , MANNING, Lourdes, P. , KAUL, Dilip
IPC: A61K31/425
CPC classification number: A61K31/635 , A61K9/4858 , A61K31/00 , A61K31/425 , A61K31/426 , A61K31/427 , A61K31/47 , A61K31/472 , A61K31/4725 , A61K31/496 , A61K31/551
Abstract: A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelating capsule or soft elastic gelating capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.
Abstract translation: 公开了一种药物组合物，其包含HIV蛋白酶抑制化合物在包含药学上可接受的醇的药学上可接受的有机溶剂中的溶液。 组合物可以任选地包含药学上可接受的酸或药学上可接受的酸的组合。 该溶液可任选地包封在硬胶凝胶囊或软弹性凝胶胶囊中。 该溶液可以任选地用药学上可接受的制粒剂造粒。
-
公开(公告)号：WO1995020384A1
公开(公告)日：1995-08-03
申请号：PCT/US1995000232
申请日：1995-01-03
Applicant: ABBOTT LABORATORIES
Inventor： ABBOTT LABORATORIES , AL-RAZZAK, Laman , MARSH, Kennan, C. , MANNING, Lourdes, P. , KAUL, Dilip
IPC: A61K31/425
CPC classification number: A61K9/0095 , A61K9/4858 , A61K31/425 , A61K47/10 , A61K47/14 , A61K47/44 , C07D277/28 , Y10S514/885 , Y10S514/974
Abstract: A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1): (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol (40) hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof; and (2) ethanol or propylene glycol.
Abstract translation: 公开了一种药物组合物，其包含HIV药物抑制化合物在药学上可接受的有机溶剂中的溶液，其包含（1）：（a）选自丙二醇和聚乙二醇的溶剂的混合物或（b）选自聚氧乙烯甘油 聚乙二醇（40）氢化蓖麻油，分馏椰子油，聚氧乙烯（20）脱水山梨糖醇单油酸酯和2-（2-乙氧基乙氧基）乙醇或（c）它们的混合物; 和（2）乙醇或丙二醇。
-
4.发明公开
公开(公告)号：EP0732923A1
公开(公告)日：1996-09-25
申请号：EP95906790.0
申请日：1995-01-03
Applicant: Abbott Laboratories
Inventor： AL-RAZZAK, Laman , MARSH, Kennan, C. , MANNING, Lourdes, P. , KAUL, Dilip
CPC classification number: A61K9/0095 , A61K9/4858 , A61K31/425 , A61K47/10 , A61K47/14 , A61K47/44 , C07D277/28 , Y10S514/885 , Y10S514/974
Abstract: A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1): (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol (40) hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof; and (2) ethanol or propylene glycol.
-
公开(公告)号：EP0719142A1
公开(公告)日：1996-07-03
申请号：EP94927973.0
申请日：1994-08-30
Applicant: ABBOTT LABORATORIES
Inventor： AL-RAZZAK, Laman, A. , MARSH, Kennan, C. , MANNING, Lourdes, P. , KAUL, Dilip
CPC classification number: A61K31/635 , A61K9/4858 , A61K31/00 , A61K31/425 , A61K31/426 , A61K31/427 , A61K31/47 , A61K31/472 , A61K31/4725 , A61K31/496 , A61K31/551
Abstract: A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a pharmaceutically acceptable alcohol. The composition can optionally comprise a pharmaceutically acceptable acid or a combination of pharmaceutically acceptable acids. The solution can optionally be encapsulated in hard gelating capsule or soft elastic gelating capsules. The solution can optionally be granulated with a pharmaceutically acceptable granulating agent.
-
Patent Agency Ranking6.发明公开FLAVORING SYSTEMS FOR PHARMACEUTICAL COMPOSITIONS AND METHODS OF MAKING SUCH COMPOSITIONS 审中-公开AROMA系统用于药物组合物及其方法
公开(公告)号：EP1315487A2
公开(公告)日：2003-06-04
申请号：EP01968449.7
申请日：2001-09-04
Applicant: Abbott Laboratories
Inventor： ALANI, Laman , GAUWITZ, Donald, P. , KAUL, Dilip , LIPARI, John, M. , GHOSH, Soumojeet , MARSH, Kennan, C. , WHELAN, Richard, H. , PETROSSIAN, Vanik, D.
IPC: A61K31/425 , A61K31/505 , A61K9/10
CPC classification number: A61K9/0095 , A61K31/426 , A61K31/513
Abstract: A flavoring system for a liquid pharmaceutical composition and pharmaceutical compositions containing such flavoring systems are disclosed. Flavoring systems of the invention include at least one sweetening agent, at least two flavored ingredients, and at least one flavor modifier selected from the group consisting of citric acid, sodium citrate, sodium chloride, and mixtures thereof. At least two of the flavored ingredients are selected from the group consisting of a vanilla flavored ingredient, a peppermint flavored ingredient, a menthol flavored ingredient, a cotton candy flavored ingredient, and mixtures thereof. The one or more sweetening agents comprise glycerin, monoammonium glycyrrhizinate, saccharin sodium, acesulfame potassium, high fructose corn syrup, and/or mixtures thereof. Pharmaceutical compositions of the invention include a flavoring system of the invention, a solvent system, and at least one pharmaceutically active agent, such as lopinavir or derivatives thereof, ritonavir or derivatives thereof, or mixtures thereof. Methods for making such liquid pharmaceutical compositions are also disclosed.
-
公开(公告)号：EP0942721A1
公开(公告)日：1999-09-22
申请号：EP97947510.0
申请日：1997-11-12
Applicant: Abbott Laboratories
Inventor： LIPARI, John , AL-RAZZAK, Laman, A. , GHOSH, Soumojeet , GAO, Rong , KAUL, Dilip
CPC classification number: A61K38/55 , A61K9/4858 , A61K31/341 , A61K31/426 , A61K31/4433 , A61K31/47 , A61K31/4704 , A61K31/4725 , A61K31/496 , A61K31/513 , A61K31/5375 , A61K31/551 , A61K38/05 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/44 , Y02A50/465
Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).
Abstract translation: 公开了作为HIV蛋白酶抑制剂的化合物提供改善的口服生物利用度的液体药物组合物。 特别地，组合物包含在（a）HIV蛋白酶抑制剂和任选的（b）表面活性剂的药学上可接受的有机溶剂中的溶液。 该组合物可以任选地包封在硬凝胶胶囊或软弹性胶囊（SEC）中。
-
8.发明授权LIQUID COMPOSITION COMPRISING AN HIV PROTEASE INHIBITOR AND A C12-C18 FATTY ACID 失效液体组成，HIV蛋白酶抑制剂和C12-C18脂肪酸含
公开(公告)号：EP0942721B1
公开(公告)日：2003-01-22
申请号：EP97947510.0
申请日：1997-11-12
Applicant: Abbott Laboratories
Inventor： LIPARI, John , AL-RAZZAK, Laman, A. , GHOSH, Soumojeet , GAO, Rong , KAUL, Dilip
IPC: A61K31/425 , A61K31/535 , A61K31/55 , A61K47/10 , A61K47/12 , A61K9/48
CPC classification number: A61K38/55 , A61K9/4858 , A61K31/341 , A61K31/426 , A61K31/4433 , A61K31/47 , A61K31/4704 , A61K31/4725 , A61K31/496 , A61K31/513 , A61K31/5375 , A61K31/551 , A61K38/05 , A61K47/10 , A61K47/12 , A61K47/26 , A61K47/44 , Y02A50/465
Abstract: A liquid pharmaceutical composition providing improved oral bioavailability is disclosed for compounds which are inhibitors of HIV protease. In particular, the composition comprises a solution in a pharmaceutically acceptable organic solvent of (a) the HIV protease inhibitor and optionally, (b) a surfactant. The composition can optionally be encapsulated in either hard gelatin capsules or soft elastic capsules (SEC).
-
9.发明授权
公开(公告)号：EP0732923B1
公开(公告)日：2001-12-12
申请号：EP95906790.1
申请日：1995-01-03
Applicant: Abbott Laboratories
Inventor： AL-RAZZAK, Laman , MARSH, Kennan, C. , MANNING, Lourdes, P. , KAUL, Dilip
IPC: A61K31/425 , A61K9/08 , A61K47/10 , A61K47/12 , A61K47/14
CPC classification number: A61K9/0095 , A61K9/4858 , A61K31/425 , A61K47/10 , A61K47/14 , A61K47/44 , C07D277/28 , Y10S514/885 , Y10S514/974
Abstract: A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1): (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol (40) hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof; and (2) ethanol or propylene glycol.
-
公开(公告)号：EP0969856B1
公开(公告)日：2005-01-05
申请号：EP98910361.9
申请日：1998-03-12
Applicant: Abbott Laboratories
Inventor： ALANI, Laman, A. , CONSTANTINIDES, Panayiotis, Pericleous , KAUL, Dilip , LIPARI, John, M. , McCHESNEY-HARRIS, Lisa, L. , ABDULLAH, Bashar, Y.
CPC classification number: A61K9/1075 , A61K9/4858 , A61K38/13 , A61K47/10 , A61K47/26 , A61K47/44 , Y02A50/465 , Y10S514/885 , Y10S514/975
Abstract: Binary pharmaceutical compositions comprising (i) a cyclosporine compound, (ii) a hydrophilic phase and (iii) a surfactant provide bioavailability of the active ingredient which is equivalent to that provided by ternary compositions, but without the need for a lipophilic phase.
-
-
-
-
-
-
-
-
-
Search Results
12
records
(took 0.034 seconds)
